FDA puts Geron's (GERN) IND application for imetelstat on full clinical hold. This stops the Phase 2 trial for essential thrombocythemia and the Phase 2 for multiple myeloma. It will probably delay the start of the Phase 2 for myelofibrosis.
Imetelstat may be toxic to the liver based on abnormal function tests.
Geron must determine if the effects are reversible upon cessation on the drug.